Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.385 +0.155 (+1.68%)
Streaming Delayed Price Updated: 1:36 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Appoints Amie Krause as Chief People Officer
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Appoints Venkat Ramanan as Chief Financial Officer
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces First Quarter 2026 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
From https://immatics.com/
Via GlobeNewswire
News headline image
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Full Year 2025 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces $125 Million Underwritten Offering
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Third Quarter 2025 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
From https://immatics.com/
Via GlobeNewswire
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
From https://immatics.com/
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immatics Announces Second Quarter 2025 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces First Quarter 2025 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Full Year 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
News headline image
Immatics Announces Pricing of $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
News headline image
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? ↗
Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.